Observational Study to Collect Tissue Samples and Train a Live Tumor Diagnostic Platform for Predicting Response to Immune Checkpoint Inhibitors in Various Solid Tumors

What this Trial Is About

Researchers are studying how well a live tumor diagnostic platform called Elephas can predict how patients respond to various immunotherapies and chemoimmunotherapies across different types of tumors. This observational basket trial includes patients with several advanced or recurrent cancers who are receiving immune checkpoint inhibitor treatments. The study aims to improve understanding of tumor response to these therapies by collecting tissue samples and clinical data. Participants undergo tissue biopsies for research purposes, which may be done alongside their regular care biopsies or as separate procedures if needed. Blood samples may also be collected optionally. During the study, patients receive their usual checkpoint inhibitor treatments and standard tumor assessments as part of their care. This design allows researchers to analyze tissue and blood samples while monitoring treatment responses. Throughout the study period, participants will have their tumor status assessed regularly according to standard care. Researchers will evaluate the accuracy of the Elephas Score in predicting clinical response over up to three years for both neoadjuvant and locally advancedmetastatic patients. The study involves reviewing medical records and monitoring patient outcomes to validate this tumor diagnostic platform. Follow-up assessments will continue as participants receive their treatments and progress through their cancer care journey.

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform